APOL1 Risk Variants and Cardiovascular Disease: Results from the AASK (African American Study of Kidney Disease and Hypertension)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 9, 2017, Pages 1765-1769

  Chen, Teresa K ^a   Appel, Lawrence J ^a,b   Grams, Morgan E ^a,b   Tin, Adrienne ^b,c   Choi, Michael J ^a   Lipkowitz, Michael S ^d   Winkler, Cheryl A ^e   Estrella, Michelle M ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; coronary artery disease; heart failure; hypertension; myocardial infarction

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; APOLIPOPROTEIN L1; HIGH DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; GENOTYPE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; EPIDEMIOLOGY; ETHNOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; UNITED STATES;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEIN L1; APOLIPOPROTEINS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; UNITED STATES;

EID: 85020201144     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309384     Document Type: Article

References (24)

1. van der Velde M, Matsushita K, Coresh J, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341-1352. doi: 10.1038/ki.2010.536.
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-352. doi: 10.1016/S0140-6736(13)60595-4.
3. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081. doi: 10.1016/S0140-6736(10)60674-5.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307-1315.
5. Elliott MK, McCaughan JA, Fogarty DG. Do patients with chronic kidney disease get optimal cardiovascular risk reduction? Curr Opin Nephrol Hypertens. 2014;23:267-274. doi: 10.1097/01.mnh.0000444913.78536.b1.
6. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841-845. doi: 10.1126/science.1193032.
7. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128:345-350. doi: 10.1007/s00439-010-0861-0.
8. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129-2137. doi: 10.1681/ASN.2011040388.
9. Lipkowitz MS, Freedman BI, Langefeld CD, et al; SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83:114-120. doi: 10.1038/ki.2012.263.
10. Parsa A, Kao WH, Xie D, et al; AASK Study Investigators; CRIC Study Investigators. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183-2196. doi: 10.1056/NEJMoa1310345.
11. Ito K, Bick AG, Flannick J, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014;114:845-850. doi: 10.1161/CIRCRESAHA.114.302347.
12. Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, Kaysen GA, Kimmel PL, Raj DS, Ricardo AC, Wright JT Jr, Sedor JR, Rocco MV, Freedman BI; Systolic Blood Pressure Intervention Trial (SPRINT). Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015;87:169-175. doi: 10.1038/ki.2014.254.
13. Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM, Hicks PJ, Xu J, Wagenknecht LE, Raffield LM, Register TC, Carr JJ, Bowden DW, Divers J. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015;87:176-181. doi: 10.1038/ki.2014.255.
14. Freedman BI, Gadegbeku CA, Bryan RN, et al; African American-Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int. 2016;90:440-449. doi: 10.1016/j.kint.2016.04.027.
15. Grams ME, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, Appel LJ, Tin A, Coresh J. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27:2842-2850. doi: 10.1681/ ASN.2015070763.
16. Mukamal KJ, Tremaglio J, Friedman DJ, Ix JH, Kuller LH, Tracy RP, Pollak MR. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol. 2016;36:398-403. doi: 10.1161/ATVBAHA.115.305970.
17. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, Malloy MJ, Kane JP. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 1997;272:25576-25582.
18. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol. 2011;22:2119-2128. doi: 10.1681/ ASN.2011010069.
19. Ma L, Shelness GS, Snipes JA, et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol. 2015;26:339-348. doi: 10.1681/ASN.2013091017.
20. Ma L, Langefeld CD, Comeau ME, Bonomo JA, Rocco MV, Burkart JM, Divers J, Palmer ND, Hicks PJ, Bowden DW, Lea JP, Krisher JO, Clay MJ, Freedman BI. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease. Kidney Int. 2016;90:389-395. doi: 10.1016/j.kint.2016.02.032.
21. Appel LJ, Middleton J, Miller ER 3rd, et al. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14(7 suppl 2):S166-S172.
22. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739-751. doi: 10.1053/j.ajkd.2006.08.004.
23. Alves TP, Wang X, Wright JT Jr, Appel LJ, Greene T, Norris K, Lewis J; AASK Collaborative Research Group. Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol. 2010;21:1361-1369. doi: 10.1681/ASN.2009060654.
24. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol. 2012;23:1929-1939. doi: 10.1681/ASN.2012010037.